

Consolidated Financial Results for the Nine Months Ended December 31, 2022 [JGAAP]

Phone: +81-3-4236-8801

Scheduled date to commence dividend payments:

February 10, 2023

Company Name: Kanto Denka Kogyo Co., Ltd. Stock Exchange Listing: Tokyo

Code Number: 4047 https://www.kantodenka.co.jp/english/

Representative: Jun'ichi Hasegawa, President

Contact: Masanobu Shirokura, General Manager, Legal & General Affairs

Scheduled date for submitting the Quarterly Securities Report:

February 10, 2023

2022)

Availability of supplementary briefing material on financial results: None

Financial results briefing session: None

1. Consolidated financial results for the third quarter of the fiscal year ending March 31, 2023 (April 1, 2022–December 31,

(Amounts are rounded down to the nearest million yen)

(1) Consolidated operating results

| (1) Consolidated operating results | r-on-year increase or | decrease) | | | | | | |
|-------------------------------------|-----------------------|-----------|------------------|-------|-----------------|-------|---|-------|
| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | |
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % |
| Nine months ended December 31, 2022 | 57,207 | 27.8 | 9,895 | 23.5 | 10,917 | 36.4 | 7,860 | 40.0 |
| Nine months ended December 31, 2021 | 44,764 | 19.6 | 8,013 | 122.2 | 8,001 | 129.5 | 5,616 | 183.9 |

(Note) Comprehensive income:

Nine months ended December 31, 2022: ¥9,198 million (59.9%) Nine months ended December 31, 2021: ¥5,753 million (78.6%)

| | Basic earnings per share | Diluted basic earnings per share |
|-------------------------------------|--------------------------|----------------------------------|
| | Yen | Yen |
| Nine months ended December 31, 2022 | 136.82 | _ |
| Nine months ended December 31, 2021 | 97.76 | |

(2) Consolidated financial position

| | Total assets | Net assets | Equity ratio | Net assets per share |
|-------------------------|-----------------|-----------------|--------------|----------------------|
| | Millions of yen | Millions of yen | % | Yen |
| As of December 31, 2022 | 129,239 | 67,268 | 51.1 | 1,149.52 |
| As of March 31, 2022 | 109,902 | 59,908 | 53.0 | 1,014.01 |

(Note) Equity capital:

As of December 31, 2022: ¥66,043 million As of March 31, 2022: ¥58,254 million

2. Dividends

| | End of 1Q | End of 2Q | End of 3Q | Year-end | Total |
|-----------------------------------|-----------|-----------|-----------|----------|-------|
| | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ended March 31, 2022 | _ | 8.00 | _ | 14.00 | 22.00 |
| Fiscal year ending March 31, 2023 | _ | 10.00 | _ | | |
| Fiscal year ending March 31, 2023 | | | | 22.00 | 32.00 |
| (Forecast) | | | | | |

(Note) Revision of dividend forecast from the latest announcement: None

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2023 (April 1, 2022–March 31, 2023)

| | e of year- | on-year increase or decrease) | | | | | | | |
|-----------|-----------------|-------------------------------|------------------|------|-----------------|------|---|------|--------------------------|
| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | | Basic earnings per share |
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen |
| Full year | 80,000 | 28.4 | 12,300 | 10.2 | 13,400 | 20.2 | 9,300 | 19.8 | 161.87 |

(Note) Revision of performance forecast from the latest announcement: Yes

Notes:

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in changes in scope of consolidation):

Not applicable

New: — companies (company names); Removed: — companies (company names)

- (2) Application of special accounting for preparing quarterly consolidated financial statements: Yes
- (3) Changes in accounting policies, changes in accounting estimates and retrospective restatement
 - i. Changes in accounting policies accompanying amendments to accounting standards, etc.: None
 - ii. Changes in accounting policies other than i.: None
 - iii. Changes in accounting estimates: None
 - iv. Retrospective restatement: None
- (4) Number of shares issued (common stock)
 - i. Number of shares issued at the end of the period (including treasury shares)
 - ii. Number of treasury shares at the end of the period
 - iii. Average number of shares during the period

| As of December 31, 2022 | 57,546,050 shares | As of March 31, 2022 | 57,546,050 shares |
|-------------------------|-------------------|-------------------------|-------------------|
| As of December 31, 2022 | 93,137 shares | As of March 31, 2022 | 96,900 shares |
| As of December 31, 2022 | 57,451,016 shares | As of December 31, 2021 | 57,448,354 shares |

Notes:

- Summary of financial results are not subject to audit by a certified public accountant or an auditing firm.
- Proper use of performance forecasts, and other special matters

(Notes to forward-looking statements)

The performance outlooks and other forward-looking statements in this document are based on information currently available to the Company and certain assumptions that the Company deems reasonable, and are not intended to be a promise by the Company that they will be realized. Actual results may differ significantly due to various factors. Please refer to "Consolidated earnings forecasts" on page 3 of the attached materials for information on the performance forecasts.

Contents

| 1. (| Qualitative information on the first nine months ended December 31, 2022 |
|------|---|
| | (1) Operating results |
| | (2) Financial position |
| | (3) Consolidated earnings forecasts |
| 2. | Consolidated financial statements and notes |
| | (1) Consolidated balance sheet |
| | (2) Consolidated statement of income and consolidated statement of comprehensive income |
| | (Consolidated statement of income) |
| | (Consolidated Statement of Comprehensive Income) |
| | (3) Notes to the consolidated financial statements |
| | (Notes on premise of going concern) |
| | (Notes on significant changes in the amount of shareholders' equity) |
| | (Application of special accounting for preparing quarterly consolidated financial statements) |
| | (Segment information) |

(1) Operating results

In the first nine months of the fiscal year ending March 31, 2023, while the Japanese economy showed signs of recovery due to effects of various government policies, severe conditions continued to prevail amid factors such as rising raw material and fuel prices, and sharp fluctuations in exchange rates. Overseas, outlooks remained uncertain due to the need for caution amid downside risks from such factors as the prolonged situation in Ukraine and fluctuations in financial and capital markets.

Amid this business environment, net sales for the first nine months ended December 31, 2022 amounted to \$57,207 million, up \$12,442 million or 27.8% year on year, due to significantly higher sales in the Fine Chemicals Division supported by strong demand. For profits, ordinary profit amounted to \$10,917 million, up \$2,915 million or 36.4%, mainly due to higher sales in the Fine Chemicals Division despite increased raw material and fuel prices. Profit attributable to owners of parent amounted to \$7,860 million, up \$2,244 million or 40.0%.

The following provides an overview for each segment.

a. Fundamental Chemicals Division

Sales of caustic soda and hydrochloric acid were up due to effects from price revisions, despite lower sales volumes.

For organic products, sales of trichloroethylene were up due to effects from price revisions, despite lower sales volumes. Sales of perchloroethylene were up due to effects from price revisions.

As a result of the above, net sales in the Fundamental Chemicals Division amounted to \$46,469 million, up \$781 million or 13.7% year on year. Operating profit totaled \$128 million (versus operating loss of \$55 million in the previous nine months).

b. Fine Chemicals Division

For fluorochemicals for semiconductors and liquid crystals, sales of nitrogen trifluoride were up year on year due to effects from price revisions, despite lower sales volumes. Sales of tungsten hexafluoride and hexafluoro-1,3-butadiene were up due to higher sales volumes.

Sales of lithium hexafluorophosphate, a battery material, were up due to higher sales volumes and effects from price revisions.

As a result of the above, net sales in the Fine Chemicals Division amounted to \$46,736 million, up \$11,581 million or 32.9% year on year. Operating profit amounted to \$8,984 million, up \$1,895 million or 26.7%.

c. Ferrochemicals Division

Sales of reprographic carriers, used in developers for copiers and printers, were up year on year due to higher sales volumes. Sales of iron oxide were down due to lower sales of colorants.

As a result of the above, net sales in the Ferrochemicals Division amounted to \(\frac{\pma}{2}\),016 million, up \(\frac{\pma}{9}\)8 million or 5.1% year on year. Operating profit amounted to \(\frac{\pma}{5}\)10 million, up \(\frac{\pma}{107}\) million or 26.7%.

d. Commercial Business Division

Commercial business sales were down due to lower sales of chemical products.

As a result of the above, net sales in the Commercial Business Division amounted to ¥565 million, down ¥29 million or 4.9% year on year. Operating profit amounted to ¥153 million, up ¥8 million or 5.6%.

e. Facilities Division

Net sales in chemical facility plant and general industrial plant construction were up year on year due to an increase in contract work.

As a result of the above, net sales in the Facilities Division amounted to \(\xi\)1,419 million, up \(\xi\)10 million or 0.7% year on year. Operating profit amounted to \(\xi\)470 million, up \(\xi\)96 million or 26.0%.

(2) Financial position

As of the end of the third quarter of the fiscal year ending March 31, 2023, assets amounted to \(\frac{\pmathbf{1}}{29,239}\) million, up \(\frac{\pmathbf{1}}{19,337}\) million from the end of the previous consolidated fiscal year, mainly due to increases in inventories, property, plant and equipment, notes and accounts receivable—trade, and contract assets, despite a decrease in cash and deposits.

Liabilities totaled \(\frac{4}{61},971\) million, up \(\frac{4}{11},978\) million, mainly due to increases in borrowings and notes and accounts payable—trade.

Net assets amounted to \(\frac{4}{67}\),268 million, up \(\frac{4}{7}\),359 million, mainly due to an increase in retained

earnings. The equity ratio was 51.1%, versus 53.0% at the end of the previous fiscal year.

(3) Consolidated earnings forecasts

The consolidated earnings forecast for the fiscal year ending March 31, 2023 has been revised from the previous forecast announced on November 11, 2022. For details, please refer to the "Notice of Revision of Earnings Forecasts" (in Japanese only) released separately.

The above forecasts were created based on information available as of the date of this document's publishing, and actual results may differ versus forecast figures due to a variety of factors arising in the future.

2. Consolidated financial statements and notes

(1) Consolidated balance sheet

| | | (Millions of yen) |
|--|----------------------|-------------------------|
| | As of March 31, 2022 | As of December 31, 2022 |
| Assets: | | |
| Current assets | | |
| Cash and deposits | 26,728 | 22,891 |
| Notes and accounts receivable—trade, and contract assets | 16,921 | 21,428 |
| Electronically recorded monetary claims—operating | 1,101 | 1,510 |
| Merchandise and finished goods | 5,182 | 6,545 |
| Work in process | 4,416 | 9,337 |
| Raw materials and supplies | 3,526 | 6,186 |
| Other | 3,896 | 5,903 |
| Allowance for doubtful accounts | (68) | (64) |
| Total current assets | 61,705 | 73,739 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 8,872 | 9,979 |
| Machinery and equipment, net | 11,655 | 18,203 |
| Construction in progress | 11,001 | 10,313 |
| Other, net | 6,692 | 6,766 |
| Total property, plant and equipment | 38,221 | 45,264 |
| Intangible assets | 728 | 730 |
| Investments and other assets | | |
| Investment securities | 7,464 | 7,254 |
| Deferred tax assets | 1,165 | 1,289 |
| Other | 621 | 966 |
| Allowance for doubtful accounts | (4) | (6) |
| Total investments and other assets | 9,246 | 9,505 |
| Total non-current assets | 48,196 | 55,500 |
| Total assets | 109,902 | 129,239 |

| | | (Millions of yen) | |
|--|----------------------|-------------------------|--|
| | As of March 31, 2022 | As of December 31, 2022 | |
| Liabilities: | | | |
| Current liabilities | | | |
| Notes and accounts payable—trade | 8,068 | 10,435 | |
| Electronically recorded obligations—operating | 835 | 1,724 | |
| Short-term borrowings | 4,200 | 4,533 | |
| Current portion of long-term borrowings | 5,886 | 7,029 | |
| Income taxes payable | 2,600 | 1,432 | |
| Provision for bonuses for directors (and other officers) | 134 | 75 | |
| Other | 5,540 | 6,909 | |
| Total current liabilities | 27,265 | 32,140 | |
| Non-current liabilities | | | |
| Long-term borrowings | 20,166 | 27,257 | |
| Provision for retirement benefits for directors (and other officers) | 137 | 137 | |
| Provision for share awards for directors (and other officers) | 11 | 16 | |
| Retirement benefit liability | 1,754 | 1,650 | |
| Other | 657 | 768 | |
| Total non-current liabilities | 22,727 | 29,830 | |
| Total liabilities | 49,993 | 61,971 | |
| Net assets: | | | |
| Shareholders' equity | | | |
| Capital | 2,877 | 2,877 | |
| Capital surplus | 1,829 | 1,859 | |
| Retained earnings | 50,483 | 56,963 | |
| Treasury shares | (68) | (65) | |
| Total shareholders' equity | 55,122 | 61,634 | |
| Accumulated other comprehensive income | | | |
| Valuation difference on available-for-sale securities | 2,527 | 2,446 | |
| Foreign currency translation adjustment | 413 | 1,617 | |
| Remeasurements of defined benefit plans | 191 | 344 | |
| Total accumulated other comprehensive income | 3,132 | 4,408 | |
| Non-controlling interests | 1,654 | 1,225 | |
| Total net assets | 59,908 | 67,268 | |
| Total liabilities and net assets | 109,902 | 129,239 | |
| | | | |

(2) Consolidated statement of income and consolidated statement of comprehensive income

Consolidated statement of income

(Millions of yen)

| | | (Millions of yen) |
|--|---|---|
| | From April 1, 2021 to December 31, 2021 | From April 1, 2022 to December 31, 2022 |
| Net sales | 44,764 | 57,207 |
| Cost of sales | 30,404 | 40,241 |
| Gross profit | 14,360 | 16,965 |
| Selling, general and administrative expenses | 6,346 | 7,069 |
| Operating profit | 8,013 | 9,895 |
| Non-operating profit | | |
| Interest income | 2 | 12 |
| Dividend income | 203 | 243 |
| Foreign exchange gains | 94 | 618 |
| Gain on sale of trial products | - | 271 |
| Other | 212 | 194 |
| Total non-operating profit | 513 | 1,340 |
| Non-operating expenses | | |
| Interest expenses | 206 | 232 |
| Loss on valuation of derivatives | 88 | 47 |
| Loss on sale of trial products | 179 | - |
| Other | 49 | 39 |
| Total non-operating expenses | 524 | 319 |
| Ordinary profit | 8,001 | 10,917 |
| Extraordinary income | | |
| Gain on sale of investment securities | 131 | - |
| Total extraordinary income | 131 | - |
| Extraordinary losses | | |
| Loss on retirement of non-current assets | 29 | 163 |
| Loss on valuation of investment securities | - | 17 |
| Total extraordinary losses | 29 | 180 |
| Profit before income taxes | 8,103 | 10,736 |
| Income taxes payable | 2,294 | 2,810 |
| Profit | 5,808 | 7,926 |
| Profit attributable to non-controlling interests | 192 | 65 |
| Profit attributable to owners of parent | 5,616 | 7,860 |

| | From April 1, 2021 to December 31, 2021 | From April 1, 2022 to December 31, 2022 |
|---|--|--|
| Profit | 5,808 | 7,926 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | (202) | (133) |
| Foreign currency translation adjustment | 149 | 1,251 |
| Remeasurements of defined benefit plans | (2) | 153 |
| Total other comprehensive income | (54) | 1,272 |
| Comprehensive income | 5,753 | 9,198 |
| Comprehensive income attributable to: | | |
| Owners of parent | 5,491 | 9,136 |
| Non-controlling interests | 262 | 61 |

(3) Notes to the consolidated financial statements

(Notes on premise of going concern) Not applicable.

(Notes on significant changes in the amount of shareholders' equity) Not applicable.

(Application of special accounting for preparing quarterly consolidated financial statements)

Tax expenses are calculated by multiplying profit before income taxes by the reasonably estimated effective tax rate after the application of tax effect accounting to profit before income taxes for the fiscal year ending March 31, 2023, including the third quarter under review. However, in cases where calculating tax expenses using the estimated effective tax rate would significantly lack rationality, tax expenses are calculated using the statutory effective tax rate.

(Segment information)

- I. From April 1, 2021 to December 31, 2021
- 1. Information on net sales, profit or loss by reportable segment

(Millions of ven)

| | Fundamental Chemicals | Fine Chemicals | Reportable s | egment Commercial Business | Facilities | Total | Adjustment (Note 1) | Amount recorded on the statement of income (Note 2) |
|---|--------------------------|-------------------|--------------|-----------------------------|------------|--------|------------------------|--|
| Net sales (1) Net sales to external customers | 5,688 | 35,154 | 1,917 | 594 | 1,409 | 44,764 | _ | 44,764 |
| (2) Inter-segment net sales or transfers | _ | _ | 0 | 1,010 | 2,255 | 3,266 | (3,266) | _ |
| Total | 5,688 | 35,154 | 1,917 | 1,605 | 3,665 | 48,030 | (3,266) | 44,764 |
| Segment profit (loss) | (55) | 7,089 | 402 | 145 | 373 | 7,955 | 58 | 8,013 |

- (Notes) 1. The segment profit (loss) adjustment of ¥58 million is elimination of inter-segment transactions.
 - 2. Segment profit (loss) is adjusted with operating profit in the consolidated statement of income.
- Information about impairment loss and goodwill on non-current assets by reportable segment Not applicable.
- II. From April 1, 2022 to December 31, 2022
- 1. Information on net sales, profit or loss by reportable segment

(Millions of yen)

| | Fundamental Chemicals | Fine Chemicals | Reportable s | Commercial Business | Facilities | Total | Adjustment (Note 1) | Amount recorded on the statement of income (Note 2) |
|--|--------------------------|-------------------|--------------|------------------------|------------|--------|------------------------|--|
| Net sales (1) Net sales to external customers | 6,469 | 46,736 | 2,016 | 565 | 1,419 | 57,207 | _ | 57,207 |
| (2) Inter-segment net sales or transfers | _ | | 0 | 1,075 | 2,782 | 3,858 | (3,858) | _ |
| Total | 6,469 | 46,736 | 2,016 | 1,641 | 4,202 | 61,065 | (3,858) | 57,207 |
| Segment profit | 128 | 8,984 | 510 | 153 | 470 | 10,246 | (350) | 9,895 |

- (Notes) 1. The segment profit adjustment of \$350 million is elimination of inter-segment transactions.
 - 2. Segment profit is adjusted with operating profit in the consolidated statement of income.
- 2. Information about impairment loss and goodwill on non-current assets by reportable segment Not applicable.